Inhaled nitric oxide: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
==Administration== | ==Administration== | ||
*Type: | *Type: Inhalational agent | ||
*Dosage Forms: | *Dosage Forms: Metal cylinders | ||
*Routes of Administration: | *Routes of Administration: Inhaled | ||
*Common Trade Names: | *Common Trade Names: | ||
==Adult Dosing== | ==Adult Dosing== | ||
Revision as of 23:59, 26 April 2016
Administration
- Type: Inhalational agent
- Dosage Forms: Metal cylinders
- Routes of Administration: Inhaled
- Common Trade Names:
Adult Dosing
5 - 80 ppm
Pediatric Dosing
Special Populations
Renal Dosing
- Adult:
- Pediatric:
Hepatic Dosing
- Adult:
- Pediatric:
Contraindications
- Allergy to class/drug
Adverse Reactions
Serious
- Hypotension
- Inhibits platelets - bleeding
- Rebound htn and hypoxia
- Renal failure
Common
Pharmacology
- Half-life: 5 seconds
- Metabolism: reacts with oxyhemoglobin to form methemoglobin and nitrate, and also reacts with deoxy-Hb.
- Excretion: Urinary; 70% of inhaled NO excreted within 48 hrs as nitrate
Mechanism of Action
- Acts via diffusion from alveoli
- Relaxes smooth muscle of pulmonary vessels via conversion of GTP to cGMP, which activates a phosphorylatio cascade
- Enhances V/Q matching by increasing blood flow to well-ventilated areas of lung
- Decreases PVR
- Decreases PA pressure
Indications
- Pulmonary HTN of newborn
- Pulmonary HTN of adults
- Right heart failure (post-VAD, transplant, post cardiac surgery)
- Graft failure post lung transplant
Comments
See Also
References
- Ichinose F, Roberts JD Jr, Zapol WM. Inhaled nitric oxide: a selective pulmonary vasodilator: current uses and therapeutic potential. Circulation. 2004 Jun 29;109(25):3106-11. Review. PubMed PMID: 15226227.